Matches in SemOpenAlex for { <https://semopenalex.org/work/W2933386824> ?p ?o ?g. }
- W2933386824 endingPage "57" @default.
- W2933386824 startingPage "49" @default.
- W2933386824 abstract "Cancer is still a leading of cause of death worldwide. Among the bio-therapy strategies for cancer, vaccinia virus (VV) has been widely used as an expression vector because of its potent oncolytic activities in addition to its large capacity for insertion of foreign genes and excellent safety records. In the present study, a novel recombinant VV, VV-HBD2-lacZ, expressing human β-defensin 2 (HBD2), an anti-microbial peptide of the innate immune system, was constructed. First, the chemotaxis characteristics of HBD2 expressed on VV-HBD2-lacZ-infected cells toward dendritic cells (DCs) in vitro and in vivo were demonstrated. The anti-tumor effects of VV-HBD2-lacZ in vitro and in vivo in a mouse melanoma cancer model were then investigated. It was found that VV-HBD2-lacZ was able to inhibit tumor growth and metastasis significantly. It was further demonstrated that VV-HBD2-lacZ induced potent cytotoxic activity by increasing the tumor-infiltrating CD4+ and CD8+ T cells. These results indicate that HBD2-expressing VV recruited plasmacytoid DCs (pDCs) to the tumor location, leading to cytotoxic T cell response against the tumor, and thus inhibited tumor growth in vitro and in vivo. In conclusion, oncolytic HBD2-expressing VV provides an effective treatment for tumors by triggering innate and adaptive immunity. Cancer is still a leading of cause of death worldwide. Among the bio-therapy strategies for cancer, vaccinia virus (VV) has been widely used as an expression vector because of its potent oncolytic activities in addition to its large capacity for insertion of foreign genes and excellent safety records. In the present study, a novel recombinant VV, VV-HBD2-lacZ, expressing human β-defensin 2 (HBD2), an anti-microbial peptide of the innate immune system, was constructed. First, the chemotaxis characteristics of HBD2 expressed on VV-HBD2-lacZ-infected cells toward dendritic cells (DCs) in vitro and in vivo were demonstrated. The anti-tumor effects of VV-HBD2-lacZ in vitro and in vivo in a mouse melanoma cancer model were then investigated. It was found that VV-HBD2-lacZ was able to inhibit tumor growth and metastasis significantly. It was further demonstrated that VV-HBD2-lacZ induced potent cytotoxic activity by increasing the tumor-infiltrating CD4+ and CD8+ T cells. These results indicate that HBD2-expressing VV recruited plasmacytoid DCs (pDCs) to the tumor location, leading to cytotoxic T cell response against the tumor, and thus inhibited tumor growth in vitro and in vivo. In conclusion, oncolytic HBD2-expressing VV provides an effective treatment for tumors by triggering innate and adaptive immunity." @default.
- W2933386824 created "2019-04-11" @default.
- W2933386824 creator A5003274543 @default.
- W2933386824 creator A5017975397 @default.
- W2933386824 creator A5019117674 @default.
- W2933386824 creator A5040186544 @default.
- W2933386824 creator A5085455612 @default.
- W2933386824 date "2019-06-01" @default.
- W2933386824 modified "2023-10-16" @default.
- W2933386824 title "Recombinant Oncolytic Vaccinia Viruses Expressing Human β-Defensin 2 Enhance Anti-tumor Immunity" @default.
- W2933386824 cites W135540365 @default.
- W2933386824 cites W1757407923 @default.
- W2933386824 cites W1965497380 @default.
- W2933386824 cites W1978558644 @default.
- W2933386824 cites W1991186601 @default.
- W2933386824 cites W1991218000 @default.
- W2933386824 cites W1996881279 @default.
- W2933386824 cites W2020849247 @default.
- W2933386824 cites W2022175692 @default.
- W2933386824 cites W2031576296 @default.
- W2933386824 cites W2054458001 @default.
- W2933386824 cites W2068527013 @default.
- W2933386824 cites W2069891242 @default.
- W2933386824 cites W2079647238 @default.
- W2933386824 cites W2104159258 @default.
- W2933386824 cites W2104518375 @default.
- W2933386824 cites W2108595427 @default.
- W2933386824 cites W2108860192 @default.
- W2933386824 cites W2108883303 @default.
- W2933386824 cites W2113321923 @default.
- W2933386824 cites W2147979551 @default.
- W2933386824 cites W2153328681 @default.
- W2933386824 cites W2161162286 @default.
- W2933386824 cites W2179183038 @default.
- W2933386824 cites W2183585286 @default.
- W2933386824 cites W2279131089 @default.
- W2933386824 cites W2324080174 @default.
- W2933386824 cites W2401279933 @default.
- W2933386824 cites W2586317281 @default.
- W2933386824 cites W2731599079 @default.
- W2933386824 cites W2771271245 @default.
- W2933386824 cites W2789330529 @default.
- W2933386824 cites W2793196876 @default.
- W2933386824 cites W2889085114 @default.
- W2933386824 cites W2897731374 @default.
- W2933386824 cites W4211177539 @default.
- W2933386824 doi "https://doi.org/10.1016/j.omto.2019.03.010" @default.
- W2933386824 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6463222" @default.
- W2933386824 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31011627" @default.
- W2933386824 hasPublicationYear "2019" @default.
- W2933386824 type Work @default.
- W2933386824 sameAs 2933386824 @default.
- W2933386824 citedByCount "9" @default.
- W2933386824 countsByYear W29333868242019 @default.
- W2933386824 countsByYear W29333868242020 @default.
- W2933386824 countsByYear W29333868242021 @default.
- W2933386824 countsByYear W29333868242022 @default.
- W2933386824 countsByYear W29333868242023 @default.
- W2933386824 crossrefType "journal-article" @default.
- W2933386824 hasAuthorship W2933386824A5003274543 @default.
- W2933386824 hasAuthorship W2933386824A5017975397 @default.
- W2933386824 hasAuthorship W2933386824A5019117674 @default.
- W2933386824 hasAuthorship W2933386824A5040186544 @default.
- W2933386824 hasAuthorship W2933386824A5085455612 @default.
- W2933386824 hasBestOaLocation W29333868241 @default.
- W2933386824 hasConcept C104317684 @default.
- W2933386824 hasConcept C121608353 @default.
- W2933386824 hasConcept C150903083 @default.
- W2933386824 hasConcept C154317977 @default.
- W2933386824 hasConcept C167672396 @default.
- W2933386824 hasConcept C202751555 @default.
- W2933386824 hasConcept C203014093 @default.
- W2933386824 hasConcept C207001950 @default.
- W2933386824 hasConcept C2777701055 @default.
- W2933386824 hasConcept C2780674031 @default.
- W2933386824 hasConcept C2781356689 @default.
- W2933386824 hasConcept C40767141 @default.
- W2933386824 hasConcept C502942594 @default.
- W2933386824 hasConcept C54355233 @default.
- W2933386824 hasConcept C55493867 @default.
- W2933386824 hasConcept C82210918 @default.
- W2933386824 hasConcept C86803240 @default.
- W2933386824 hasConcept C8891405 @default.
- W2933386824 hasConcept C96232424 @default.
- W2933386824 hasConceptScore W2933386824C104317684 @default.
- W2933386824 hasConceptScore W2933386824C121608353 @default.
- W2933386824 hasConceptScore W2933386824C150903083 @default.
- W2933386824 hasConceptScore W2933386824C154317977 @default.
- W2933386824 hasConceptScore W2933386824C167672396 @default.
- W2933386824 hasConceptScore W2933386824C202751555 @default.
- W2933386824 hasConceptScore W2933386824C203014093 @default.
- W2933386824 hasConceptScore W2933386824C207001950 @default.
- W2933386824 hasConceptScore W2933386824C2777701055 @default.
- W2933386824 hasConceptScore W2933386824C2780674031 @default.
- W2933386824 hasConceptScore W2933386824C2781356689 @default.
- W2933386824 hasConceptScore W2933386824C40767141 @default.
- W2933386824 hasConceptScore W2933386824C502942594 @default.
- W2933386824 hasConceptScore W2933386824C54355233 @default.